Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx

Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j

Does Sunlight Trigger Lupus? Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could.https://t.co/IYhPv0dB9Z https://t.co/cza7qGSCbu

Does Sunlight Trigger Lupus?

Save

Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could.

Read Article

CC Genotype and Thiopurine Toxicity

Save

Annals of Internal Medicine reports that thiopurine toxcicity risk is associated with the "CC" genotype and that azathioprine discontinuation was associated with hematopoietic toxicity and lower thiopurine doses. 

Read Article

Study of 1778 #SLE pts, of whom 121 had refractory thrombocytopenia (TP)(Plt <50K, unresp. to pred), Risk factors included pregnancy, Autoimmune hemolytic anemia, decreased C3, severity of TP and elevated ACL-IgG. https://t.co/ZNqQfUoYUq https://t.co/eQNcKcc9Uz

#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj

Watch: Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE Dr. Yusof interviews Dr. Lucy Carter ( @LucyCarter6), winner of the #EULAR2022 Best Abstract Award for her work on ANA positivity in those at-risk for progression to #SLE. https://t.co/BdPnZRgwX4 https://t.co/g8xWWFthVC

Improved Pregnancy Outcomes in SLE (2010–2020)

Save

A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).

Read Article

What do our lupus patients think about treat-to-target?

Save

In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/concern?

Read Article

Cluster study of 383 aPL+ pts showed 4 clusters: Cluster 1 (138): w/ SLE & non-criteria Sxs Cluster 2 (112): pts w/ CV risks Cluster 3 (83): females w/ OB morbidity (BEST outcome) Cluster 4 (50): lupus anticoagulant (+) (high freq of arterial thrombosis) https://t.co/HGRTceplsn https://t.co/ZDdwhCmj5r

Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ

Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit

#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer

Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Emerging Therapeutics for Lupus

Save

Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast. 

Read Article

EULAR 2022 – Day 4 Report

Save

Bags are packed, ready to go, but wait there’s more abstracts to show.

The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article

Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee

Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9